Tag: Alexion Pharmaceuticals
Alexion to acquire genetic medicine company LogicBio Therapeutics
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the ... Read More
AstraZeneca acquisition of Alexion comes under UK CMA’s scanner
The UK Competition and Markets Authority (CMA) has launched a phase 1 merger inquiry into $39 billion AstraZeneca’s acquisition of Alexion Pharmaceuticals, a US biopharma ... Read More
AstraZeneca shareholders approve $39bn acquisition of Alexion
AstraZeneca has secured its shareholders’ approval for its previously announced $39 billion acquisition of US biopharma company Alexion Pharmaceuticals. The pharma giant expects the acquisition ... Read More
AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn
AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in ... Read More
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is ... Read More
Alexion Pharmaceuticals to acquire Portola Pharmaceuticals for $1.4bn
Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. ... Read More
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More
Alexion Pharmaceuticals bags Ultomiris FDA approval for atypical HUS
Ultomiris FDA approval : Alexion Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) for the treatment of atypical ... Read More
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal ... Read More
Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria
Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More